Mavacamten: New Drug for Hypertrophic Cardiomyopathy & Improved Heart Health
Berlin, Germany – In a significant advancement for cardiology, the Italian Medicines Agency (AIFA) has approved reimbursement for mavacamten, a novel treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM). This decision, announced in November 2025, offers new hope for individuals living with this often debilitating heart condition, providing a targeted therapy option where standard treatments have … Read more